Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequen...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690883/ |
| id |
pubmed-4690883 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-46908832016-01-04 Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma Kato, Koji Akashi, Koichi Review Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy. MDPI 2015-12-14 /pmc/articles/PMC4690883/ /pubmed/26694446 http://dx.doi.org/10.3390/v7122960 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kato, Koji Akashi, Koichi |
| spellingShingle |
Kato, Koji Akashi, Koichi Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| author_facet |
Kato, Koji Akashi, Koichi |
| author_sort |
Kato, Koji |
| title |
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| title_short |
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| title_full |
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| title_fullStr |
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| title_full_unstemmed |
Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma |
| title_sort |
recent advances in therapeutic approaches for adult t-cell leukemia/lymphoma |
| description |
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy. |
| publisher |
MDPI |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690883/ |
| _version_ |
1613516661611036672 |